Skip to Main Content


Skip Nav Destination


Journal Archive

Cancer Immunology Research (2013-Present)

(ISSN 2326-6066) Published monthly since 2013.

Cancer Immunity (2001-2013; volumes 1-13)

(EISSN 1424-9634) Published periodically from 2001-2013.

Table of Contents

What We're Reading

In the Spotlight



Priority Brief

The authors show that differences in the cytokine profiles of transgenic cellular immunotherapies for solid tumors have implications for therapeutic efficacy. These differences should be considered when developing future generations of cellular therapies to augment clinical response rates.

Research Articles

The impact of antigen priming–induced metabolic and epigenetic alterations on iNKT-cell function is revealed. The data provide a deeper understanding of how metabolic wiring affects antitumor responses and highlight potential approaches to enhance efficacy of iNKT cell–based immunotherapies.

A metabolic CRISPR–Cas9 screen reveals the important role of fucosylation in the suppressive function of Tregs. Measuring fucosylation in Tregs has the potential to aid in the discovery of relevant prognostic markers for cancer patients.

Understanding how tumor-antigen type (tumor-specific versus self/shared) determines T-cell states could provide insights into responses to ICB. The authors show SSA-reactive CD8+ T cells enter and persist in a previously undescribed TCF1+PD1 memory-like state, lacking effector function.

By studying how antitumor immune responses can be mediated against cancers that are B2M-deficient, and therefore cannot be recognized by cytotoxic CD8+ T cells, the authors provide new understanding of the mechanism of action of ICB therapies.

The authors explore the therapeutic potential of VISTA in bladder cancer, finding it is mainly expressed on macrophages and predicts poor patient prognosis. Preclinical analyses identify the underlying mechanisms and suggest combining a VISTA-specific mAb and TLR3-specific adjuvant.

Using a hybrid sequencing approach, SF3B1-independent alternative splicing events and novel isoforms in uveal melanoma are identified. These neoepitopes are immunogenic and can activate antitumor T-cell responses, highlighting them as potential therapeutic targets in uveal melanoma.

Close Modal

or Create an Account

Close Modal
Close Modal